Sign in

NCT02485015Active, not recruitingPhase 2

The Study of Apatinib Plus CIK as the Third Line Therapy for Patients With Advanced Gastric Cancer

The Randomized, Controlled, Multicenter Clinical Trial of Apatinib Plus CIK as the Third Line Therapy for Patients With Advanced Gastric Cancer

Source: ClinicalTrials.gov · Last updated 19 Feb 2016

Brief summary (registry, in English)

The purpose of this study is to evaluate the safety and efficacy of Apatinib combined with cytokine-induced killer cell (CIK) vs Apatinib as the third line therapy for patients with advanced gastric cancer.

Status (registry)
Active, not recruiting
Phase (registry)
Phase 2
Study type
Interventional
Enrollment
80 (actual)
First submitted
24 Jun 2015
Start date
1 Jun 2015
Primary completion date
30 Jun 2030
Lead sponsor
The First People's Hospital of Changzhou
NCT number
NCT02485015

What you commit to

  • Study type: Interventional · Phase 2
  • Participants enrolled: 80
  • From 1 Jun 2015 to the primary completion date, 30 Jun 2030
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Known or suspected allergy to the investigational agent or any agent given in association with this trial

Other illness

  • Known history of Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV) or TreponemaPallidun (TP) infection
  • Patients who are suffering from serious autoimmune disease
  • Patients who had active infection
  • Patients who are suffering from other cancer

Lab values

  • Hemoglobin\<8.0 g/dL,White blood cell \<3 X 10\^9/L;Platelet count \<75 X 10\^9/L; alanine aminotransferase, glutamic-oxalacetic transaminase, blood urine nitrogen and creatinine more than normal limits on 3.0 times

Other

  • Pregnant or lactating patients
  • Patients who had used long time or are using immunosuppressant
  • Patients who are suffering from serious organ dysfunction
  • Other situations that the researchers considered unsuitable for this study.

Who the study is looking for

  • Patients who can accept curative operations 18-70 years old
  • Histologically confirmed with gastric cancer at stage Ⅳ
  • Patients who can accept oral drugs;
  • Eastern Cooperative Oncology Group (ECOG) performance status was 0 - 1.

Age in the registry: 18 years to 70 years · Sex: Female · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.